Major Lectureships and Seminars
- “Innovations in Pediatric Heart Failure,” symposium, San Diego, Calif., December 2015
- Invited faculty, Barth Syndrome Foundation Biannual Conference, Clearwater Beach, Fla., July 2016
- “Management of the Highly Allosensitized Pediatric Heart Transplant Patient,” Invited presenter, Optum Conference, Pittsburgh, Pa., May 2016
- Invited faculty, 8th Annual Neonatal and Pediatric ECMO Conference, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pa., August 2016
- Invited faculty, International Society of Heart and Lung Transplantation Annual Scientific Sessions, San Diego, Calif., April 2017
Professional Affiliations/Society Memberships
- Society for Pediatric Research
- AHAFellow, AHA
- Council on Cardiovascular Disease in the Young, AHA
- International Pediatric Transplant Association
- American Society of Transplantation
- International Society for Heart and Lung Transplantation
- Grant review panelist, NIH/National Heart, Lung, and Blood Institute Pediatric Heart Network Clinical Research Centers
- Grant review panelist, AHA Strategically Focused Research Network Phase One
Listing Strategies for Allosensitized Pediatric Heart Transplant Candidates. Brian Feingold was awarded a five-year NIH KL2 grant in July 2010 to determine historical outcomes for children listed for heart transplantation with a requirement for prospective crossmatch. This includes modeling outcomes for two competing wait-list strategies for allosensitized patients. Analyses are being performed with data from the United Network for Organ Sharing and PHTS databases and have resulted in multiple publications.
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Non-adherence Role of Alloantibodies in Cardiac Transplantation: Intervention, Outcomes, and Mechanisms. Feingold is the Children’s Hospital site primary investigator on this NIH NIAID award. This program (CTOT-C) seeks to enhance understanding of the role of alloantibodies in pediatric heart transplantation. Pediatric heart transplant candidates are frequently allosensitized based on prior exposure to blood products, and homografts, and ventricular assist devices, and this has led to increased pre- and post-transplant mortality. This research program brings together a group of seven leading heart transplant centers and leading transplantation scientists to study the impact of preformed and de novo alloantibodies on mid-term pediatric heart transplant outcomes. Mechanistic studies are being performed to determine why some children develop graft injury but others appear to “accommodate” their grafts in the presence of donor-specific antibody and a positive donor-specific cross-match.
Epstein-Barr Virus (EBV) Infection in the Immunocompromised Host. Primary EBV infection is a major cause of morbidity and mortality after pediatric thoracic organ transplantation and frequently is associated with the development of post-transplant lymphoproliferative disorder (PTLD). Feingold serves as a co-investigator on Diana Metes’ NIH R01, which is examining chronic high EBV load and the risk of PTLD in pediatric thoracic transplant patients.
sST2/IL33 as a Biomarker for Acute Rejection in Pediatric Heart Transplant Recipients. In this collaboration with Heth Turnquist from the Thomas E. Starzl Transplantation Institute, the team is seeking noninvasive markers of acute rejection. This research is supported by the Roche Organ Transplantation Research Foundation.
Cardiac Fibrosis after Pediatric Heart Transplantation. In collaboration with investigators at the cardiac magnetic resonance imaging center at UPMC Presbyterian, Feingold and colleagues are working toward quantifying fibrosis after pediatric heart transplantation, determining risk factors, and elucidating mechanisms for development. Fibrosis occurs variably after transplantation and is thought to be associated with limitations in late post-transplant survival.
Pediatric Cardiomyopathy—Biomarkers. This NIH-funded consortium of pediatric heart failure centers is working together to understand the utility of blood and imaging biomarkers in the diagnosis and prognosis of cardiomyopathies. Feingold serves as site primary investigator.
Non-invasive Detection of Acute Rejection. Feingold has partnered with an industry sponsor and the Hillman Transplant Foundation to explore possible clinical biomarkers for the diagnosis of acute heart transplant rejection.
Heart Transplantation in Barth Syndrome. This study, funded in part by the Barth Syndrome Foundation, seeks to quantify the world experience and outcomes of heart transplantation for individuals with Barth Syndrome.